Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 6
2007 3
2008 4
2009 2
2010 4
2012 2
2013 4
2014 2
2015 4
2016 5
2017 7
2018 4
2019 9
2020 11
2021 4
2022 7
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Results by year

Filters applied: . Clear all
Page 1
REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T, Kudo M, Ikeda K, Izumi N, Tateishi R, Ikeda M, Aikata H, Kawaguchi Y, Wada Y, Numata K, Inaba Y, Kuromatsu R, Kobayashi M, Okusaka T, Tamai T, Kitamura C, Saito K, Haruna K, Okita K, Kumada H. Yamashita T, et al. Among authors: wada y. J Gastroenterol. 2020 Jan;55(1):113-122. doi: 10.1007/s00535-019-01642-1. Epub 2019 Nov 12. J Gastroenterol. 2020. PMID: 31720835 Free PMC article. Clinical Trial.
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Kudo M, et al. Among authors: wada y. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4. Gut. 2020. PMID: 31801872 Free PMC article. Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Ann Oncol. 2024 Feb 19:S0923-7534(24)00049-8. doi: 10.1016/j.annonc.2024.02.005. Online ahead of print. Ann Oncol. 2024. PMID: 38382875 Free article.
Lenvatinib as an Initial Treatment in Patients with Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child-Pugh A Liver Function: A Proof-Of-Concept Study.
Kudo M, Ueshima K, Chan S, Minami T, Chishina H, Aoki T, Takita M, Hagiwara S, Minami Y, Ida H, Takenaka M, Sakurai T, Watanabe T, Morita M, Ogawa C, Wada Y, Ikeda M, Ishii H, Izumi N, Nishida N. Kudo M, et al. Among authors: wada y. Cancers (Basel). 2019 Jul 31;11(8):1084. doi: 10.3390/cancers11081084. Cancers (Basel). 2019. PMID: 31370183 Free PMC article.
A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
Kudo M, Ueshima K, Saeki I, Ishikawa T, Inaba Y, Morimoto N, Aikata H, Tanabe N, Wada Y, Kondo Y, Tsuda M, Nakao K, Ito T, Hosaka T, Kawamura Y, Kuzuya T, Nojiri S, Ogawa C, Koga H, Hino K, Ikeda M, Moriguchi M, Hisai T, Yoshimura K, Furuse J, Arai Y. Kudo M, et al. Among authors: wada y. Liver Cancer. 2023 Jun 5;13(1):99-112. doi: 10.1159/000531377. eCollection 2024 Feb. Liver Cancer. 2023. PMID: 38344448 Free PMC article.
Recent Developments in Preclinical DNA Vaccination.
Okuda K, Wada Y, Shimada M. Okuda K, et al. Among authors: wada y. Vaccines (Basel). 2014 Jan 13;2(1):89-106. doi: 10.3390/vaccines2010089. Vaccines (Basel). 2014. PMID: 26344468 Free PMC article. Review.
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
Niizeki T, Tokunaga T, Takami Y, Wada Y, Harada M, Shibata M, Nakao K, Sasaki R, Hirai F, Shakado S, Yoshizumi T, Itoh S, Yatsuhashi H, Bekki S, Ido A, Mawatari S, Honda K, Sugimoto R, Senju T, Takahashi H, Kuwashiro T, Maeshiro T, Nakamuta M, Aratake Y, Yamashita T, Otsuka Y, Matsumoto S, Sohda T, Shimose S, Murotani K, Tanaka Y. Niizeki T, et al. Among authors: wada y. Target Oncol. 2022 Nov;17(6):643-653. doi: 10.1007/s11523-022-00921-x. Epub 2022 Oct 22. Target Oncol. 2022. PMID: 36272060 Free PMC article.
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma.
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Moriguchi M, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Ogasawara S, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y. Kudo M, et al. Among authors: wada y. Liver Cancer. 2022 Feb 10;11(4):354-367. doi: 10.1159/000522547. eCollection 2022 Jul. Liver Cancer. 2022. PMID: 35978604 Free PMC article.
Iron Deficiency Anemia Improved by Dental Implantation: A Case Report.
Yamamoto H, Wada Y, Ito S, Kawase T, Tamura M. Yamamoto H, et al. Among authors: wada y. Saudi J Med Med Sci. 2022 Jan-Apr;10(1):67-71. doi: 10.4103/sjmms.sjmms_353_21. Epub 2022 Jan 12. Saudi J Med Med Sci. 2022. PMID: 35283702 Free PMC article.
71 results